Although gene edited animal models are very powerful tools for biomedical research, genetically modified cell lines have many advantages including convenience, fast timeline, and low cost.

In addition to our knockout cell lines, our gene editing services for knockin cell lines include free preliminary evaluation experiments, single cell colonization, genotyping and validation, tumor formation experiments, and FACS analysis.

Application Example #1:

A knockin cell line model was generated with EGFP inserted at the translation initiation site of ACTB (cytoskeleton filiform protein) in the U2OS cell line (human osteosarcoma). 

ACTB gene encodes β-actin, a cytoskeletal protein. The homologous arms of the targeting vector are about 1 kb, and the homologous recombination of the target vector was done by CRISPR/cas9 based EGE™ technology.

A similar gene editing strategy was used for LMNB1, which encodes the nucleoprotein Lamin-B1.

In U2OS cells, flow cytometry plots show that the efficiency of EGFP-ACTB gene knockin mediated by EGE™ (15.02%) is 8 times higher compared to CRISPR/Cas9-mediated knockin (1.91%). In the C6 cell line, the EGE™ system improves the knockin efficiency of EGFP-LMNB1 to 3.6% from 0.19%, which is a 19-fold increase.

Application Example #2:

Gene editing of hESCs and iPSCs

The highly efficient EGE™ system is ideal for editing the genomes of induced pluripotent stem cells (iPSCs) and human embryonic stem cells (hESCs) . 

Multiple iPSC lines are reprogrammed from human fibroblasts by non-integrated plasmids. Panel A shows phase contrast images. This iPSC knockin cell line expresses the pluripotency markers OCT4, SSEA-4 and TRA-1-60 as shown in Panel B and have a normal karyotype (Panel C) . Teratoma forms in immunodeficient mice (Panel D).

Human-Pluripotent-Stem-Cell

Humanized Tumor Cell Lines

Attention: Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.

Product Organism Disease
B-hB7-H3 MC38 Mus musculus, mouse Colon Carcinoma
B-hBCMA MC38 Mus musculus, mouse Colon Carcinoma
B-hCCR4 MC38 Mus musculus, mouse Colon Carcinoma
B-hCD19 MC38 Mus musculus, mouse Colon Carcinoma
B-hCD20 MC38 Mus musculus, mouse Colon Carcinoma
B-hCD39 MC38 Mus musculus, mouse Colon Carcinoma
B-hCD47 MC38 Mus musculus, mouse Colon Carcinoma
B-hCD47 MC38 Plus Mus musculus, mouse Colon Carcinoma
B-hCD73 MC38 Mus musculus, mouse Colon Carcinoma
B-hCEACAM1 MC38 Mus musculus, mouse Colon Carcinoma
B-hCLDN18.2 MC38 Mus musculus, mouse Colon Carcinoma
B-hCXCR2 MC38 Mus musculus, mouse Colon Carcinoma
B-hEPCAM MC38 Mus musculus, mouse Colon Carcinoma
B-hHLA-E MC38 plus Mus musculus, mouse Colon Carcinoma
B-hHVEM MC38 Mus musculus, mouse Colon Carcinoma
B-hPD-L1 MC38 Mus musculus, mouse Colon Carcinoma
B-hPD-L1 MC38 Plus Mus musculus, mouse Colon Carcinoma
B-hPD-L1 low MC38 Mus musculus, mouse Colon Carcinoma
B-hPD-L1 plus/hCD47 MC38 Mus musculus, mouse Colon Carcinoma
B-hPD-L1 plus/hCEA MC38 Mus musculus, mouse Colon Carcinoma
B-hPD-L2 MC38 Mus musculus, mouse Colon Carcinoma
B-hROR1 MC38 Mus musculus, mouse Colon Carcinoma
B-hSIGLEC15 MC38 Mus musculus, mouse Colon Carcinoma
B-hTNFR2 MC38 Mus musculus, mouse Colon Carcinoma
B-hTPBG MC38 Mus musculus, mouse Colon Carcinoma
B-mSiglec15 MC38 Mus musculus, mouse Colon Carcinoma

Luciferase Reporter Tumor Cell Lines

Attention: Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.

Humanized Tumor Cell lines

Product Organism Disease
B-hCD38 MC38 Mus musculus, mouse Colon Carcinoma